Transitioning from NAFLD to MAFLD to MASLD in the Mexican population

Transitioning from NAFLD to MAFLD to MASLD in the Mexican population

Saved in:

Bibliographic Details
Main Authors:	B.A. Priego-Parra, R. Bernal-Reyes, M.E. Icaza-Chávez, S.E. Martínez-Vázquez, J.M. Remes-Troche
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	Revista de Gastroenterología de México (English Edition)
Online Access:	http://www.sciencedirect.com/science/article/pii/S2255534X25000222
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Transitioning from NAFLD to MAFLD and MASLD: the toxic relationship with alcohol consumption
by: Mubin Ozercan, et al.
Published: (2025-01-01)

Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders
by: Hong-ye Peng, et al.
Published: (2025-05-01)

MASLD vs. MAFLD. A narrative review
by: Amedeo Lonardo, et al.
Published: (2025-08-01)

Exploring the diagnostic accuracy of MAFLD, MASLD and metabolic syndrome in individuals with and without steatosis.
by: Mariana M. Ramírez-Mejía, et al.
Published: (2025-04-01)

Association between exposure to air pollutants and NAFLD/MAFLD: a meta-analysis
by: Zixiao Zhu, et al.
Published: (2025-08-01)

P-61 CLINICAL APPLICATION OF NAFLD FIBROSIS SCORE AND HEPAMET FIBROSIS SCORE IN CORONARY ARTERY DISEASE AND MASLD: A CROSS-SECTIONAL STUDY IN WESTERN MEXICAN POPULATION
by: José Antonio Velarde Chávez, et al.
Published: (2024-12-01)

Comparative association between NAFLD and MAFLD with cardiovascular events and mortality: Evidence from observational studies.
by: Taoli Fu, et al.
Published: (2025-01-01)

Comparative association between NAFLD and MAFLD with cardiovascular events and mortality: Evidence from observational studies
by: Taoli Fu, et al.
Published: (2025-01-01)

Bile acid malabsorption (BAM): A rarely suspected cause of chronic diarrhea – Towards an efficient and economic diagnosis
by: J.M. Remes-Troche
Published: (2025-04-01)

Mala absorción de ácidos biliares (MAAB): una causa pocas veces sospechada de diarrea crónica. Hacia un diagnóstico eficiente y económico
by: J.M. Remes-Troche
Published: (2025-04-01)

Tradition and advancement: 90 years of excellence of the Asociación Mexicana de Gastroenterología
by: J.M. Remes-Troche
Published: (2025-01-01)

Comment on “MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease”
by: Ying Ma, et al.
Published: (2025-01-01)

From NAFLD to MASLD – a new approach for the definition of fatty liver disease associated with metabolic dysfunction
by: Iwona Gorczyca-Głowacka, et al.
Published: (2025-01-01)

Correlation of Cardiovascular Risk Score with Alterations in Carotid Intima-Media Thickness in Patients with MASLD
by: José L. Vargas-Basurto, et al.
Published: (2025-04-01)

Editorial: Nutriomic analysis of food and functional compounds for MAFLD prevention
by: Fermin I. Milagro, et al.
Published: (2025-08-01)

Non-invasive methods for diagnosing portal hypertension and variceal bleeding due to liver cirrhosis secondary to NAFLD/MASLD: systematic review
by: Nebyu Yonas Shanka, et al.
Published: (2025-01-01)

Exploring the knowledge and attitudes towards metabolic dysfunction associated fatty liver disease (MAFLD): Validation and correlations of MAFLD-knowledge questionnaire and MAFLD-attitude questionnaire
by: Samah Al Tawil, et al.
Published: (2024-11-01)

Cannabinoid hyperemesis syndrome: A review
by: R.A. Jiménez-Castillo, et al.
Published: (2025-04-01)

Síndrome de hiperémesis cannabinoide: una revisión
by: R.A. Jiménez-Castillo, et al.
Published: (2025-04-01)

Global burden of MAFLD, MAFLD related cirrhosis and MASH related liver cancer from 1990 to 2021
by: Ziwei Guo, et al.
Published: (2025-02-01)

Dietary characteristics of Mexican patients with irritable bowel syndrome: Is there a distinction from the general population?
by: M. Amieva-Balmori, et al.
Published: (2025-04-01)

Different fungal signatures in ALD and MAFLD
by: Daya Zhang, et al.
Published: (2024-11-01)

Features of Management of Patients with NAFLD and Sarcopenia
by: M. E. Statsenko, et al.
Published: (2025-05-01)

TyG-BMI as a superior predictor of MAFLD and pre-MAFLD in Chinese adults: a cross-sectional study
by: Xinru Huang, et al.
Published: (2025-07-01)

StackNAFLD: An Accurate Stacking Ensemble Learning Targeting NAFLD Treatment
by: Andi Endang Kusuma Intan, et al.
Published: (2025-08-01)

Diet, Metabolism and Innate Immune Training in individuals With MAFLD
by: Helen M Roche, et al.
Published: (2025-05-01)

Identification of Ferroptosis -Related Genes in MAFLD/MASH and HQHF Validation
by: Liu S, et al.
Published: (2025-05-01)

Milpa Diet for MASLD in Mesoamerican Populations: Feasibility, Advantages, and Future Perspectives
by: Aline Huerta-Álvarez, et al.
Published: (2025-05-01)

MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
by: Ying Wang, et al.
Published: (2025-04-01)

Metabolic dysfunction and kidney disease risk in individuals with MAFLD
by: Ziyan Pan, et al.
Published: (2025-01-01)

Diet, oxidative stress and MAFLD: a mini review
by: Zenan Hu, et al.
Published: (2025-03-01)

Immune Microenvironment on the Molecular Mechanisms and Therapeutic Targets of MAFLD
by: Jiang Z, et al.
Published: (2025-07-01)

MAFLD - a new approach to fatty liver disease
by: Borys Łozowski, et al.
Published: (2025-05-01)

Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociación Mexicana de Gastroenterología, 2024
by: J.M. Remes-Troche, et al.
Published: (2025-01-01)

The role of C-reactive protein to lymphocyte ratio in NAFLD and mortality among NAFLD patients
by: Jianxin Xi, et al.
Published: (2025-05-01)

The role of lipoprotein sulfatides in MASLD fibrosis transition: A new frontier in hepatic immunomodulation
by: Yifan Zhou, et al.
Published: (2025-03-01)

The rationale for the aggressive progression of MASLD in patients with type 2 diabetes
by: Valeria Michelle Fernández-Garibay, et al.
Published: (2025-01-01)

Identification of Ferroptosis-Related Genes in MAFLD/MASH and HQHF Validation [Corrigendum]
by: Liu S, et al.
Published: (2025-06-01)

Prevalence and associated factors of MAFLD in adults with type 2 diabetes.
by: Yifei He, et al.
Published: (2024-01-01)

Prevalence and associated factors of MAFLD in adults with type 2 diabetes
by: Yifei He, et al.
Published: (2024-01-01)